GSK files fluticasone/vilanterol combo for COPD and asthma in Japan
This article was originally published in Scrip
Executive Summary
Just two months after simultaneous filings in the US and Europe, GlaxoSmithKline has applied for the Japanese approval of its inhaled respiratory therapy combining the corticosteroid fluticasone furoate and vilanterol trifenatate, a long-acting beta2 agonist, for the treatment of asthma and chronic obstructive pulmonary disease (COPD).